CG Oncology director exercises options, sells 1,000 shares

CG Oncology, Inc. director Leonard E. Post reported an exercise-and-sale transaction plus a new option grant.

Rhea-AI Filing Summary

CG Oncology, Inc. director Leonard E. Post reported an exercise-and-sale transaction plus a new option grant. He exercised 1,000 stock options at $0.60 per share and sold 1,000 common shares at $54.50 per share under a pre-arranged Rule 10b5-1 trading plan. He also received a fully vested grant of 9,354 director stock options with a $56.09 exercise price, while another option grant for 9,354 shares vests monthly after June 4, 2026. Following these transactions, he holds 1,000 common shares and 116,077 director stock options.

Insider Trade Summary 10b5-1

Exercise and Sale: 1,000 shares ($54K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider POST LEONARD E

Role Director

Sold 1,000 shs ($55K)

Approx. gross sale proceeds $55K

Approx. exercise cost $600.00

Approx. pre-tax spread $54K

Type	Security	Shares	Price	Value
Exercise	Director Stock Option (right to buy)	1,000	$0.00	$0.00
Grant/Award	Director Stock Option (right to buy)	9,354	$0.00	$0.00
Exercise	Common Stock	1,000	$0.60	$600.00
Sale	Common Stock	1,000	$54.50	$55K

Holdings After Transaction: Director Stock Option (right to buy) — 125,431 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (3)

1. F1. The option exercise and sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026
2. F2. Fully vested.
3. F3. 1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Key Figures

Shares sold: 1,000 shares Sale price: $54.50/share Options exercised: 1,000 shares +5 more

8 metrics

Shares sold 1,000 shares Common Stock open-market sale at $54.50 on June 4, 2026

Sale price $54.50/share Price for 1,000 CG Oncology common shares sold

Options exercised 1,000 shares Common Stock acquired via option exercise at $0.60

Exercise price $0.60/share Strike price for 1,000 options converted to common stock

New option grant 9,354 options Director Stock Option grant on June 4, 2026

New option strike price $56.09/share Exercise price of newly granted director stock options

Options remaining 116,077 options Director Stock Option holdings following transactions

Option expiration June 3, 2036 Expiration date for newly granted director stock options

Key Terms

Rule 10b5-1 trading plan, Director Stock Option, Exercise or conversion of derivative security, Grant, award, or other acquisition, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The option exercise and sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Director Stock Option financial

"Director Stock Option (right to buy)"

Exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security"

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition"

vesting financial

"1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CG Oncology (CGON) director Leonard E. Post report?

Leonard E. Post reported exercising 1,000 stock options and selling 1,000 CG Oncology common shares. He also reported the grant of 9,354 director stock options and continues to hold 1,000 common shares plus 116,077 director stock options after these transactions.

At what prices did Leonard E. Post exercise and sell CG Oncology (CGON) shares?

He exercised 1,000 options at an exercise price of $0.60 per share and sold 1,000 common shares at $54.50 per share. This reflects an exercise-and-sale pattern where options are converted into shares and then sold on the open market.

Was Leonard E. Post’s CG Oncology (CGON) share sale pre-planned under Rule 10b5-1?

Yes. A footnote states the option exercise and sale were effected under a Rule 10b5-1 trading plan adopted on March 5, 2026. Such plans pre-schedule trades, indicating the timing of these transactions was set in advance rather than decided opportunistically.

What new CG Oncology (CGON) director stock options did Leonard E. Post receive?

He received a grant of 9,354 director stock options with a $56.09 exercise price. One grant is described as fully vested, while another vests in monthly installments after June 4, 2026, subject to his continued service with CG Oncology.

How many CG Oncology (CGON) securities does Leonard E. Post hold after these transactions?

After the reported transactions, he holds 1,000 CG Oncology common shares directly and 116,077 director stock options. These remaining options provide rights to purchase additional shares at specified exercise prices and future dates, according to the vesting and expiration terms disclosed.

When do Leonard E. Post’s new CG Oncology (CGON) options expire and vest?

The newly granted 9,354 director stock options have an expiration date of June 3, 2036. For one grant, one-twelfth of the total shares vest monthly after June 4, 2026, with any remaining unvested portion vesting at the next annual stockholder meeting if earlier.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

POST LEONARD E

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

3000 PEGASUS PARK DRIVE, SUITE 1640

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		M(1)		1,000	A	$0.6	1,000	D
Common Stock	06/04/2026		S(1)		1,000	D	$54.5	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$0.6	06/04/2026		M(1)			1,000	(2)	07/08/2028	Common Stock	1,000	$0	116,077	D
Director Stock Option (right to buy)	$56.09	06/04/2026		A		9,354		(3)	06/03/2036	Common Stock	9,354	$0	9,354	D

Explanation of Responses:

1. The option exercise and sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026

2. Fully vested.

3. 1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.

	/s/ Joshua Patterson, Attorney-in-Fact for Leonard Post	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)